Zu Pkt 4 – Nomogramme
Danke Low-Road,
für den link zum Webinar.
Zur Vertiefung des Themas "Nomogramme", hier die Studie mit ausführlichen Ergänzungsmaterial und einem link zum online-Risiko-Rechner.
“Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study”
“Predictors included in the nomograms were time since initial diagnosis of prostate cancer, chemotherapy status, baseline haemoglobin concentration, and [68Ga]Ga-PSMA-11 PET/CT parameters (molecular imaging TNM classification and tumour burden).”
wenig überraschend das Ergebnis:
“Compared with high-risk patients, low-risk patients had significantly longer overall survival in the validation cohort (24·9 months [95% CI 16·8–27·3] vs 7·4 months [4·0–10·8]; p<0·0001) and PSA-progression-free survival (6·6 months [6·0–7·1] vs 2·5 months [1·2–3·8]; p=0·022).”
Franz
Kommentar